Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine GlobeNewswire - Tue Jun 16, 6:01AM CDT

Invivyd expects to report topline data from LIBERTY in Q3 2026 Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis...

IVVD : 0.9144 (-5.72%)
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine... GlobeNewswire - Tue Jun 9, 6:01AM CDT

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19...

IVVD : 0.9144 (-5.72%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Jun 3, 6:01AM CDT

NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate...

IVVD : 0.9144 (-5.72%)
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID GlobeNewswire - Mon Jun 1, 6:01AM CDT

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a...

IVVD : 0.9144 (-5.72%)
Invivyd to Participate in Upcoming Investor Events GlobeNewswire - Wed May 27, 6:01AM CDT

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference...

IVVD : 0.9144 (-5.72%)
MarketBeat.com
Invivyd Q1 Earnings Call Highlights MarketBeat - Thu May 14, 11:15AM CDT

Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to...

IVVD : 0.9144 (-5.72%)
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire - Thu May 14, 6:01AM CDT

Achieved Q1 2026 PEMGARDA ® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutralizing...

IVVD : 0.9144 (-5.72%)
Invivyd's First Quarter May Show Whether Pemgarda Revenue Can Sustain Momentum—If It Shows Up Barchart - Wed May 13, 4:03PM CDT

Barchart Research What to Expect from IVVD Earnings IVVD Generated May 13, 2026 Current Price $1.4700 EPS Estimate $$-0.08 Consensus Rating Moderate Buy Average Move 6.22% Invivyd's First Quarter May Show...

IVVD : 0.9144 (-5.72%)
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination GlobeNewswire - Mon May 11, 6:01AM CDT

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues Results allow for comparison...

IVVD : 0.9144 (-5.72%)
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 GlobeNewswire - Thu May 7, 6:01AM CDT

NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that...

IVVD : 0.9144 (-5.72%)

Barchart Exclusives

The Big Tech Investment Cycle is Shifting, and Chevron Just Wrote the Blueprint for the AI Power Trade. Barchart - Mon Jun 22, 7:52PM CDT
The new partnership between energy giant Chevron and hyperscaler Microsoft highlights that the next phase of the artificial intelligence trade is plugging directly into the power grid. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.